{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:05:24Z","timestamp":1789009524314,"version":"build-2803163510"},"reference-count":22,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T00:00:00Z","timestamp":1493078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Swedish Childrens\u2019 Cancer Foundation"},{"name":"V\u00e4stra G\u00f6taland County Council"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Given that 30\u201340% of children with acute myeloid leukaemia (<jats:styled-content style=\"fixed-case\">AML<\/jats:styled-content>) relapse after primary therapy it is important to define prognostic factors and identify optimal therapy. From 1993 to 2012, 543 children from the Nordic countries were treated according to two consecutive protocols: 208 children relapsed. The influence of disease characteristics, first line treatment, relapse therapy and duration of first remission on outcome was analysed. Second complete remission (<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>2) was achieved in 146 (70%) patients. Estimated 5\u2010year overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content><jats:sub>5y<\/jats:sub>) was 39\u00a0\u00b1\u00a04% for the whole group and 43\u00a0\u00b1\u00a04% for the 190 patients given re\u2010induction therapy, of whom 76% received regimens that included fludarabine, cytarabine (<jats:styled-content style=\"fixed-case\">FLA<\/jats:styled-content>) \u00b1 anthracyclines, 18% received Nordic Society for Paediatric Haematology and Oncology (<jats:styled-content style=\"fixed-case\">NOPHO<\/jats:styled-content>) upfront blocks and 5% received other regimens. Late relapse \u22651\u00a0year from diagnosis, no allogeneic stem cell transplantation (<jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content>) in first remission and core binding factor <jats:styled-content style=\"fixed-case\">AML<\/jats:styled-content> were independent favourable prognostic factors for survival. For the 128 children (124 in <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>2) that received <jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content> as consolidation therapy after relapse, OS<jats:sub>5y<\/jats:sub> was 61\u00a0\u00b1\u00a05%. Four of 19 children (21%) survived without receiving <jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content> as part of relapse therapy. Our data show that intensive re\u2010induction followed by <jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content> can give cure rates of 40% in children with relapsed <jats:styled-content style=\"fixed-case\">AML<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/bjh.14720","type":"journal-article","created":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T06:53:27Z","timestamp":1493103207000},"page":"592-602","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Outcome after intensive reinduction therapy and allogeneic stem cell transplant in paediatric relapsed acute myeloid leukaemia"],"prefix":"10.1111","volume":"178","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1960-6796","authenticated-orcid":false,"given":"Lene","family":"Karlsson","sequence":"first","affiliation":[{"name":"Institution for Clinical Sciences Department of Paediatrics Sahlgrenska Academy, University of Gothenburg Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Forestier","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Paediatrics Umea University Umea Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Hasle","sequence":"additional","affiliation":[{"name":"Department of Paediatrics Aarhus University Hospital Skejby Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsi","family":"Jahnukainen","sequence":"additional","affiliation":[{"name":"Division of Haematology\u2010Oncology and Stem Cell Transplantation Children\u2032s Hospital Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d3lafur G.","family":"J\u00f3nsson","sequence":"additional","affiliation":[{"name":"Children\u2032s Hospital Landspitali University Hospital Hringbraut, Reykjavik Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte","family":"Lausen","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine Rigshospitalet, University of Copenhagen Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika","family":"Nor\u00e9n Nystr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Paediatrics Umea University Umea Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefine","family":"Palle","sequence":"additional","affiliation":[{"name":"Department of Women\u2032s and Children\u2032s Health Uppsala University Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tierens","sequence":"additional","affiliation":[{"name":"Department of Pathobiology and Laboratory Medicine University Health Network, Toronto General Hospital Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9008-4495","authenticated-orcid":false,"given":"Bernward","family":"Zeller","sequence":"additional","affiliation":[{"name":"Department of Paediatrics Oslo University Hospital Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Abrahamsson","sequence":"additional","affiliation":[{"name":"Institution for Clinical Sciences Department of Paediatrics Sahlgrenska Academy, University of Gothenburg Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,4,25]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06419.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.6829"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.066"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12989"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21123"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-484097"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12807."},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12900"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-416701"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12030"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.7384"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-409813"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403962"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.6321"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-261800"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.114579"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22385"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70090-5"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.127"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.7948"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401254"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.8289"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14720","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.14720","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T07:17:24Z","timestamp":1696317444000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,25]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1111\/bjh.14720"],"URL":"https:\/\/doi.org\/10.1111\/bjh.14720","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,25]]},"assertion":[{"value":"2017-01-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-04-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}